Compare ProShares UltraPro Short QQQ ETF (SQQQ) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro Short QQQ ETF vs Zoetis Inc — how do they compare? ProShares UltraPro Short QQQ ETF trades at $32.91 (market cap $2.23B), while Zoetis Inc trades at $74.76 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 13.5× ProShares UltraPro Short QQQ ETF's market cap, and Zoetis Inc pays a 2.9% dividend while ProShares UltraPro Short QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraPro Short QQQ ETF for 12 Days and Zoetis Inc for 70 Days on average.
| SQQQ | ZTS | |
|---|---|---|
Market Cap | $2.23B | $30.20B |
Volume | 60,436,012 | 6,175,327 |
Sector | Leveraged / Inverse | Health |
52-Week High | $89.43 | $147.53 |
52-Week Low | $31.83 | $69.09 |
Typical Hold Time | 12 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SQQQ trades at $32.95, up 2.71% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF shows no traditional financial ratios as it's an inverse leveraged product designed to move opposite the Nasdaq 100. Recent news highlights its role as a hedging tool against tech sector declines, with articles discussing strategic pairing with QQQ positions.
As a 3x leveraged inverse ETF, SQQQ carries significant risk from daily rebalancing and decay. It serves as a tactical tool for bearish Nasdaq 100 views or portfolio hedging, but requires active management. The primary risk remains volatility decay and timing sensitivity in a market where tech stocks have shown long-term growth trends.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
